Clinical Trials Logo

Filter by:
NCT ID: NCT03711162 Terminated - Clinical trials for Idiopathic Pulmonary Fibrosis

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

ISABELA1
Start date: November 28, 2018
Phase: Phase 3
Study type: Interventional

The main purpose of this study was to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study also investigated how well GLPG1690 is tolerated (for example if you got any side effects while on study drug).

NCT ID: NCT03650413 Terminated - Ulcerative Colitis Clinical Trials

An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

Start date: January 14, 2019
Phase: Phase 2
Study type: Interventional

This study will evaluate the long-term safety and tolerability of UTTR1147A in participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), enrolling up to 320 participants from the parent studies: Phase Ib Study GA29469 (NCT02749630) and Phase II Study GA39925 (NCT03558152).

NCT ID: NCT03639610 Terminated - Multiple Myeloma Clinical Trials

PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function

BRIDGE
Start date: August 28, 2018
Phase: Phase 2
Study type: Interventional

This was a multicenter study of the pharmacokinetics (PK) of melphalan during treatment with melflufen and dexamethasone in patients with relapsed refractory multiple myeloma (RRMM) and impaired renal function.

NCT ID: NCT03635112 Terminated - Crohn's Disease Clinical Trials

Efficacy and Safety of TD-1473 in Crohn's Disease

DIONE
Start date: November 19, 2018
Phase: Phase 2
Study type: Interventional

A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with moderately-to-severely active Crohn's Disease with up to 48 weeks of treatment.

NCT ID: NCT03629249 Terminated - Asthma Clinical Trials

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

Start date: December 13, 2018
Phase: Phase 3
Study type: Interventional

The overall purpose of this study was to determine the efficacy of fevipiprant (150 mg and 450 mg once daily), compared with placebo, as add-on to standard-of-care asthma therapy, in terms of avoidance of corticosteroid use over 52 weeks.

NCT ID: NCT03627091 Terminated - Crohn's Disease Clinical Trials

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)

CARMEN CD 307
Start date: February 6, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ontamalimab as maintenance treatment in participants with moderate to severe Crohn's disease (CD).

NCT ID: NCT03626545 Terminated - Non-Small-Cell Lung Clinical Trials

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

CANOPY-2
Start date: January 23, 2019
Phase: Phase 3
Study type: Interventional

This study was designed to evaluate the role of canakinumab in combination with docetaxel in subjects with advanced non-small cell lung cancer (NSCLC) previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy.

NCT ID: NCT03616912 Terminated - Clinical trials for Systemic Lupus Erythematosus

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

SLE-BRAVE I
Start date: August 2, 2018
Phase: Phase 3
Study type: Interventional

The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

NCT ID: NCT03615924 Terminated - Sickle Cell Disease Clinical Trials

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease

HESTIA3
Start date: September 26, 2018
Phase: Phase 3
Study type: Interventional

The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease

NCT ID: NCT03608033 Terminated - IgA Nephropathy Clinical Trials

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

Start date: February 16, 2018
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effect of OMS721 on 24-hour urine protein excretion (UPE) in IgA nephropathy (IgAN) patients with high baseline proteinuria (high-risk proteinuria group; 24-hour UPE ≥ 2 g/day) assessed at 36 weeks from baseline.